We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
VRAX | Virax Biolabs Group Ltd | 2.265 | 1.20 | 111.68% | 65,384,934 |
FRGT | Freight Technologies Inc | 1.1899 | 0.56486 | 90.37% | 174,408,876 |
TOIIW | Oncology Institute Inc | 0.0298 | 0.0131 | 78.44% | 2,760 |
WISA | WiSA Technologies Inc | 3.4512 | 1.38 | 66.72% | 22,513,053 |
SHOTW | Safety Shot Inc | 0.389 | 0.129 | 49.62% | 497 |
AEMD | Aethlon Medical Inc | 0.6017 | 0.1631 | 37.19% | 79,556,680 |
FBLG | FibroBiologics Inc | 9.16 | 2.46 | 36.72% | 530,859 |
CLEU | China Liberal Education Holdings Ltd | 1.892 | 0.472 | 33.24% | 8,672,135 |
TRSG | Tungray Technologies Inc | 4.3001 | 1.01 | 30.70% | 149,724 |
ONMD | OneMedNet Corporation | 2.055 | 0.455 | 28.44% | 6,484,511 |
AONC | American Oncology Network Inc | 2.9009 | 0.6409 | 28.36% | 1,232,107 |
WiSA Technologies, Inc. (NASDAQ: WISA), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, is pleased to report seeing continued penetration into the $296 billion wireless audio market fueled by interest in its WiSA E software.
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, ...
No Shareholder Action Required at This TimeWASHINGTON, June 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash.
The offering is comprised of 61,538,461 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.22 per share (the “Series A Warrants”) and one Series B Warrant to purchase one share of common stock at an exercise price of $0.22 per share or, pursuant to an alternative cashless exercise option, three shares of common stock at a price of $0.001 per share (the “Series B ...
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
NB | Niocorp Developments Ltd | 64 | |
FNMA | Fannie Mae-No Politics | 55 | |
RSPI | RespireRx Pharmaceuticals Inc | 116 | |
4 | RDGL | Vivos Inc | 50 |
5 | COOP | Mr Cooper Group Inc | 30 |
6 | SPZI | SPOOZ Inc | 48 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 71,500.92 | 423.63 | 0.60% | 1.41T | 3,503,774,495 |
ETH | Ethereum | 3,843.26 | -21.28 | -0.55% | 461.2B | 1,863,263,328 |
BNB | Binance Coin | 708.72 | 10.06 | 1.44% | 111.65B | 425,106,710 |
USDT | Tether USD | 0.99958 | -0.00042 | -0.04% | 97.8B | 224,198,013 |
SOL | Solana | 173.40 | -0.040 | -0.02% | 76.35B | 626,958,921 |
STETH | stETH | 3,840.78 | -21.89 | -0.57% | 37.37B | 4,955,681 |
XRP | Ripple | 0.5275 | 0.0019 | 0.36% | 28.77B | 221,306,220 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 920,185,980 |
TONCOIN | Wrapped TON Coin | 7.34 | 0.164513 | 2.29% | 25.46B | 109,187,567 |
DOGE | Dogecoin | 0.16355 | 0.00047 | 0.29% | 23.47B | 188,734,813 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions